It has been observed that a modest number of patients, suffering from both malignancies and type 2 diabetes, were successfully treated not only for their malignancies but also for diabetes when given some tyrosine kinase inhibitors, indicating that tyrosine kinases including EGFR also mediated the metabolic diseases 22, 23, 24, 25. The gene discussed is EGFR; the disease is metabolic disease.